Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 20, 2014
Pharmacy Choice - News - Front Page Healthcare News - November 20, 2014

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/20/14 - 125 Million Reasons to Develop Drugs for Kids with Cancer
Kids v Cancer is pleased to announce that a second priority review voucher was just sold by Knights Therapeutics to Gilead for $125 million. Priority review vouchers were initially created to provide faster reviews by the FDA as incentives for pharmaceutical companies to invest in new drugs and vaccines for tropical diseases. "We are thrilled th
11/20/14 - Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial In Endometrial Cancer
Aeterna Zentaris Inc. today announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina in Charleston, South Carolina, for the Company's ongoing multinational, pivotal ZoptEC Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. Also, we are very pleased to be wo
11/20/14 - Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
Anthera Pharmaceuticals, Inc. announced today it has signed a manufacturing and supply agreement with the Patheon division of DPx Holdings B.V. "This agreement represents the culmination of years of effort by Eli Lilly following their discussion with the US FDA in 2010 to develop a next-generation therapy to address the unmet needs of patient
11/20/14 - Ariad Pharmaceuticals, Inc. - Product Pipeline Review - 2014
Global Markets Direct's,' Ariad Pharmaceuticals, Inc.- Product Pipeline Review- 2014', provides an overview of the Ariad Pharmaceuticals, Inc.' s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Ariad Pharmaceuticals, Inc.' s, complete with comparative
11/20/14 - AZE Technology, Inc. Announces FDA Approval of Phoenix (Volume Registration Viewer)
AZE Technology today announces the U.S. Food and Drug Administration approval of Phoenix, a viewer developed with a completely new concept for efficient and accurate image interpretation. Phoenix is designed with background volume-processing performed at the same time as data input, and presents various dramatic outcomes that were not possible wi
11/20/14 - Brain Stimulator Method (Restore My Brain) Review Natrual Treatment For Alzheimer's, Dementia and Other Memory Loss Disorders
Professor J. Wilson and Dr. The Brain Stimulator Method also known as Restore My Brain by Professor J. Wilson and Dr. Richard Humphrey offers Alzheimer's patients with the best health related information and easy to follow tips and tricks that people can aviate into their everyday life!
11/20/14 - Cesca Therapeutics Announces Filing of U.S. Pivotal IDE Application for No-Option Critical Limb Ischemia ("CLI")
Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company developing proprietary devices and methods for cardiovascular, orthopedic and hematological/oncological procedures, today announced it has submitted an investigational device exemption application to the U.S. Food and Drug Administration for a pivotal multicenter...
11/20/14 - Cipla Announces a Distribution Agreement with Serum Institute of India for Affordable Paediatric Vaccines in Europe
Cipla Europe NV, a global pharmaceutical company is delighted to announce that it has signed a distribution agreement with Serum Institute of India Ltd.- a global leader in the production of vaccines. Under the agreement, SII will develop and manufacture paediatric vaccines, Cipla will seek European Medicines Agency approval and market the products
Cautionary Statement Regarding Forward Looking Statements. This Quarterly Report on Form 10- Q contains forward-looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934, as amended. changes in our common stock price; changes in our profitability; regulatory act
11/20/14 - Dana-Farber Cancer Institute And Astellas Announce Research Collaboration
By a News Reporter-Staff News Editor at Gene Therapy Weekly Dana-Farber Cancer Institute and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer. Nathanael Gray, Ph.D., of the Cancer Biology Department at Dana-Farber and..
11/20/14 - Developed A Non-Invasive Test That Identifies Patients At Risk Of Kidney Transplant Rejection [Global Data Point]
From a peripheral blood sample and test development easier, you can tell noninvasively and before submission of the renal graft dysfunction if the patient's immune system will reject the kidney transplant.&# x0D;. Oriol Bestard, nephrologist, University Hospital of Bellvitge and the only Spanish participant in this study explains that "the test wil
11/20/14 - EDITORIAL: Opposition to Obamacare not likely to subside [The Oklahoman, Oklahoma City]
Nov. 19 LAWRENCE R. Jacobs, the Walter F. and Joan Mondale Chair for Political Studies at the University of Minnesota, is an expert on federal health care reform. He authored a book on passage of Obamacare. In a recent Oklahoma City appearance, Jacobs predicted there won't be any major changes to the law in the near future, despite GOP control of
11/20/14 - FDA approves new, hard-to-abuse hydrocodone pill
The Food and Drug Administration approved Purdue Pharma's Hysingla ER, for patients with severe, round-the-clock pain that cannot be managed with other treatments. Purdue Pharma's new drug poses a direct commercial challenge to Zogenix's much-debated drug Zohydro, a twice-a-day hydrocodone tablet approved by the FDA last year. The FDA has been unde
11/20/14 - FDA Grants Fast Track Designation To Novavax' RSV F Vaccine
WASHINGTON- Novavax, Inc. said the U.S. Food and Drug Administration or FDA has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate or RSV F vaccine for protection of infants through maternal immunization. In 2012, the company initiated the development of its RSV F vaccine for maternal immunization and has comple
11/20/14 - Global Anesthesia Devices Market 2014-2018
Anesthesia machines are used by anesthesiologists to support the administration of anesthetic and other medical gases such as nitrous oxide. The most commonly used device is the continuous-flow anesthetic machine, which provides a continuous flow of air, containing a regulated supply of gas. The report covers the Americas, and the EMEA and APAC r
11/20/14 - Hatch Calls Out Administration's Numbers Game on ObamaCare Enrollment
Utah Senator Says, "Despite claims by this White House that the health law and its execution have been transparent, the facts continue to tell a different story." Senator Orrin Hatch, Ranking Member of the Senate Finance Committee, issued the following statement after the Centers for Medicare& Medicaid Services confirmed that marketplace enrollment
11/20/14 - Healthways Expands Reach of Dr. Dean Ornish Program for Reversing Heart Disease with Six New Agreements
Six health systems are joining forces with global well-being improvement leader Healthways, Inc., to bring the nationally renowned Dr. Healthways has finalized new agreements with Atlantic Health System in Morristown, New Jersey; Beebe Healthcare in Lewes, Delaware; CAMC Health System in Charleston, West Virginia; St. Dominic Hospital in Jackson, M
11/20/14 - Heritage Global Partners and Federal Equipment Company to Manage Disposition of State-of-the-Art Biopharmaceutical Equipment and R&D Assets
QUEBEC CITY& SAN DIEGO Heritage Global Partners, a global leader in asset advisory and auction services, and Federal Equipment Company, today announced that they are conducting two global online sales featuring the former assets of Boehringer Ingelheim, a world-leading pharmaceutical company, Laval R&D site based in Quebec City, Canada.
11/20/14 - Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that, based on information regarding recent generic introductions by Teva Pharmaceuticals on its website, it believes...
11/20/14 - JCI Pharmaceutical Co., Ltd. Receives Approval from US FDA for Colloidal Iodine Formulation
Tokyo, Nov 20, 2014 JCI Pharmaceutical Co., Ltd. has announced approval by the US FDA for its MN colloid iodine, a formulation utilizing a world-first technology for converting iodine into a colloidal state to make it absorbable into the body at a large doses. The new formulation converts iodine into a colloid state and further processes it to ma
11/20/14 - Kolltan Presents KTN3379 Clinical and Preclinical Data at International Cancer Meeting
Kolltan is a privately held biopharmaceutical company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases. In a separate presentation, Kolltan presented data from preclinical experiments in which KTN3379 inhibited both ligand dependent and ErbB2 dependent ErbB3 activation in different tumor...
11/20/14 - Laila Pharmaceuticals Pvt. Ltd. - Product Pipeline Review - 2014
Ltd.- Product Pipeline Review- 2014', provides an overview of the Laila Pharmaceuticals Pvt. Ltd.' s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Laila Pharmaceuticals Pvt. Ltd.' s, complete with comparative analysis at various stages, therapeutics
11/20/14 - Merz Pharmaceuticals GmbH - Product Pipeline Review - 2014
Global Markets Direct's,' Merz Pharmaceuticals GmbH- Product Pipeline Review- 2014', provides an overview of the Merz Pharmaceuticals GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Merz Pharmaceuticals GmbH's, complete with comparative...
11/20/14 - Navitor Pharmaceuticals Appoints Eddine Saiah, PhD, as Vice President of Drug Discovery
Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, today announced that drug industry veteran, Eddine Saiah, PhD, has joined the company as its Vice President of Drug Discovery. Dr. Saiah will be responsible for directing Navitor s research activities directed toward th
11/20/14 - New Study Finds Routine Imaging Screening of Diabetic Patients For Heart Disease Is Not Effective [Global Data Point]
Instead, high-quality diabetes care is still the most effective way for diabetics to avoid heart attacks, according to the study by researchers at the Intermountain Medical Center Heart Institute in Murray, Utah.&# x0D;. Researchers presented their findings from the study at the 2014 American Heart Association Scientific Session in Chicago on Nov.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
HIV & AIDS Testing & Reporting Guidelines
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement